Human BioSystems
OTC Bulletin Board : HBSC

Human BioSystems

June 14, 2007 07:00 ET

Human BioSystems Announces Acceptance for Publication of a Paper Evaluating Its Unique Preservation Solution in the Journal of Investigative Surgery

PALO ALTO, CALIFORNIA--(Marketwire - June 14, 2007) - Human BioSystems ("HBS" or "Company") (OTCBB:HBSC) a Silicon Valley based bio-tech company specializing in the development of unique organ, tissue and cellular preservation platforms and holder of five U.S. patents covering such technologies, has just been notified of the acceptance of a professional paper describing its unique cold-storage preservation solution by the peer-reviewed Journal of Investigative Surgery.

Luis H. Toledo, M. D., Ph.D., a leading transplantation surgeon and Director of the HBS Research Laboratory, stated, "In this study, the HBS solution out-performed preservation solutions currently considered to be the 'gold standards' in the industry." Dr. Fernando Lopez-Neblina, co-author of the paper, praised the publication saying, "This is evidence that corroborates the significant benefits of the physiologic support we have incorporated in this next generation of preservation solutions."

The HBS paper highlights the significant attributes afforded by the HBS cold preservation solution, comparing it with the other leading solutions in the field. HBS-treated rat organs out-performed the others in survival, function, microscopic appearance and assessment using the Reperfusion Damage Index (RDI).

In addition to the current cold (0(C to -4(C) preservation solution described in this publication, HBS has developed and is testing preservation solutions intended for the freezing of biological tissues. Preservation solutions able to extend the life of organs while simultaneously improving function will enable transplant centers to ensure better matches between the transplanted organs and the recipients. This will translate into better organ function and less rejection.

Dr. David Winter, President of HBS, said, "The acceptance of our paper by such a respected publication as the Journal of Investigative Surgery is suggestive of our progress in advancing biologic preservation science. We are currently in discussion with other transplant centers to corroborate and extend the current results. Our ultimate goal in this area of our preservation business is to establish market share in the transplantation solution arena."

Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.

Contact Information